OptimizeRx Corp
OPRXAbout the company
OptimizeRx Corporation operates as a digital healthcare technology company.
Investment snapshot
Positive
6
BUY / PASS
Neutral / negative
2 / 8
NEUTRAL / FAIL
Median fair value
$7.47
+1.8% vs price
Models with upside
3 / 17
Positive margin of safety
Strongest signal
9 of 12 pass — Buffett, Marks and Asness object
Key risk
14 of 16 flag OPRX's profitability — Graham, Buffett, Lynch +11 more
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | BUY | BUY · Rank #320 (Top 10.3%) | BUY | PASS | PASS | NEUTRAL | FAIL | FAIL | PASS | PASS | FAIL | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||||||
| Margin of Safety | -13.8% | -24.0% | -8.7% | N/A | N/A | N/A | +69.1% | +10.5% | N/A | N/A | +79.4% | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | TTM ended 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-12 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-13 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-08-13 Score computed: 2026-11-14 |
Where It Passes
- Debt & Leverage75% pass✓ 12✗ 3▾
9 of 12 pass — Buffett, Marks and Asness object
LT Debt vs Net Current AssetsLT Debt $17.8M vs NCA $44.4M✓GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.15, IC: 2.3x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.15✓Lynch< 0.33Cash - Long-term Debt$6.3M✓LynchPositive preferredLT Debt / Total Assets Change18.00% -> 12.11%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities5.58✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.15✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0.15✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=2.3x, D/EBITDA=1.2x✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.15✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.1450; #1484/4210 (top 35.2%)✗AsnessTop 30% of eligible cross-section - Cash Flow70% pass✓ 9✗ 3▾
7 of 10 pass — Marks, Sleep and Oshaughnessy object
Free Cash Flow Proxy$9.4M✓BuffettPositive and growingFCF Positive and Growing$18.7M✓LynchPositive and growingOperating Cash Flow$18.7M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=10.58%, ROA=2.90%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)7.4x✓Dreman< 8xP/E or FCF YieldP/E=27.2x, FCF Yield=13.5%✓PabraiP/E < 15 or FCF Yield > 10%FCF Positive7/18 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap13.3%✓Ackman>= 4%Price / FCF per Share7.4x✓Ackman<= 25Positive Operating Cash Flow frequency7/18 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$18.4M✓Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization+13.28%; #484/4519 (top 10.7%)✗OshaughnessyTop 10% of eligible cross-section
Where It Falls Short
- Profitability13% pass✓ 11✗ 24▾
14 of 16 flag OPRX's profitability — Graham, Buffett, Lynch +11 more
Positive EPS (10 years)3/18 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)3/18 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-7.2%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)10.7% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$9.4M✓BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)0.30✓Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR91.7%✓Lynch15-30% (Fast Grower); > 0% to passROE3.5%✗Lynch> 15%EBIT / Enterprise Value8.2%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=8.2%, ROC=50.3%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets2.90%✓PiotroskiROA > 0ROA Change YoY-11.75% -> 2.90% (delta: +14.65%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=10.58%, ROA=2.90%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY64.5% -> 67.3%✓PiotroskiImproved YoYPre-Tax Income / Revenue6.9%✗Dreman>= 8%Net Income / Shareholders' Equity3.5%✗Dreman> 12%Margin of SafetyP/E=27.2x, P/B=1.1x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-9.0% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency3/16 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue11.1%✗Ackman>= 15%Net Income / Shareholders Equity3.5%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-36.9% (2023) -> 10.7% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 60.0% -> 67.3%, operating margin -36.9% -> 10.7%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization+3.33%; #2266/6340 (top 35.7%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+41.60%; #906/3702 (top 24.5%)✓AsnessTop 30% of eligible cross-sectionNet income / positive book equity+3.51%; #2617/5226 (top 50.1%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0580; #2762/5884 (top 46.9%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR91.7% over 4 years✗Neff7%-20% annualizedPositive Diluted-EPS Years3/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Growth25% pass✓ 7✗ 6▾
6 of 8 flag OPRX's growth — Graham, Marks, Ackman +3 more
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)0.30✓Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR91.7%✓Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthN/A (no inventory)✓LynchInventory growth < Revenue growthEPS Growth Direction$-0.02 (2013) -> $0.27 (2025)✓DremanPositive over recent yearsEPS CAGR45.0% CAGR over 7 years✓Dreman> 5% annualizedPositive Net Income Frequency3/16 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth18.8%✓Ackman>= 5%Positive EPS Growth Frequency2/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 60.0% -> 67.3%, operating margin -36.9% -> 10.7%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR20.4%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR91.7% over 4 years✗Neff7%-20% annualized - Valuation31% pass✓ 11✗ 17▾
9 of 13 flag OPRX's valuation — Graham, Greenblatt, Dreman +6 more
Price / Book Value per Share1.1x✓Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio1.1x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)0.30✓Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value8.2%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=8.2%, ROC=50.3%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS27.2x✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)7.4x✓Dreman< 8xValuation ReasonablenessP/E=27.2x, OE Yield=6.8%✓MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldP/E=27.2x, FCF Yield=13.5%✓PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/E=27.2x, P/B=1.1x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per Share7.4x✓Ackman<= 25Price vs. Trailing Low142% of trailing low ($5.18)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization+3.33%; #2266/6340 (top 35.7%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.9481; #1584/6449 (top 24.6%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS27.2x✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share8.28x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change+108.3%✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.7136; #2177/5247 (top 41.5%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization+13.28%; #484/4519 (top 10.7%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+19.74%; #1359/6202 (top 21.9%)✗OshaughnessyTop 10% of eligible cross-section - Verdicts47% pass✓ 7✗ 8▾
Split decision: 8 FAIL · 4 PASS · 2 BUY · 2 NEUTRAL
Overall verdict✗GrahamFAIL (3/9)✗BuffettFAIL (2/9)✓LynchBUY (6/7)✓GreenblattRank #320✓PiotroskiBUY (F-Score 8)✓DremanPASS (6/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✓AckmanPASS (5/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1037/2370 (Top 43.8%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked) - Efficiency50% pass✓ 5✗ 6▾
4 of 8 pass — Buffett, Munger, Akre +1 more object
Current Ratio5.58✓Graham>= 2.0ROIC (3-5 yr avg)-57.5%✗Buffett> 10%ROIC - WACC-67.5%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)50.3%✓Greenblatt> 25%Current Ratio Change YoY2.89 -> 3.04✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.54x -> 0.62x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities5.58✓Dreman> 1.5Return on Invested Capital5.8%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-12.8%; FY2024: ROIC=-7.2%; FY2025: ROIC=6.0%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC6.0% (RR=100% x ROIC=6.0%)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/3 years above 12% (latest 6.0%)✗SleepROIC > 12% in a majority of years - Valuation models50% pass✓ 3✗ 3▾
Models split on OPRX at $7.34 — fair values range $5.92–$35.63
Graham fair value$6.45✗Graham-13.8% margin vs $7.34Buffett fair value$5.92✗Buffett-24.0% margin vs $7.34Lynch fair value$6.75✗Lynch-8.7% margin vs $7.34Munger fair value$23.72✓Munger+69.1% margin vs $7.34Pabrai fair value$8.20✓Pabrai+10.5% margin vs $7.34Ackman fair value$35.63✓Ackman+79.4% margin vs $7.34
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 1.6% of shares last year, 3.2% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $138.3Mcurrent | -- | -- | -- | $201.9Mest. | $102.5Mest. | $256.6Mest. | $306.7Mest. | $747.9Mest. |
| Revenue | $94.2M↓14% | $21.6M↓17% | $20.5M↓30% | $19.8M↓10% | $109.4M↑19% | $92.1M↑29% | $71.5M↑15% | $62.5M↑2% | $61.3M |
| Operating Income | $11.5M↑71% | $2.7M↑30% | -$88.0K↓103% | $396.0K↑119% | $11.7M↑185% | -$13.7M↑48% | -$26.4M↓115% | -$12.3M↓3504% | $361.1K |
| Net Income | $5.0M↑14656% | $1.2M↑53% | -$703.0K↓146% | -$495.0K↑77% | $5.1M↑126% | -$20.1M↓14% | -$17.6M↓54% | -$11.4M↓3125% | $378.1K |
| EPS (Diluted) | -- | $0.06↑50% | $-0.04↓150% | $-0.03↑75% | $0.27↑125% | $-1.10↓7% | $-1.03↓61% | $-0.64↓3300% | $0.02 |
| Gross Margin | — | — | — | — | 67.3%↑4% | 64.5%↑7% | 60.0%↓4% | 62.4%↑7% | 58.1% |
| Operating Margin | 12.3%↑99% | 12.4%↑57% | -0.4%↓104% | 2.0%↑121% | 10.7%↑172% | -14.9%↑60% | -36.9%↓88% | -19.7%↓3441% | 0.6% |
| ROE | 3.7%↑13376% | — | — | — | 4.0%↑123% | -17.2%↓24% | -13.9%↓53% | -9.1%↓3252% | 0.3% |
| Total Debt | $12.7M↓55% | $12.7M↓55% | $19.0M↓33% | $23.3M↓28% | $25.7M↓22% | $32.8M↓9% | $36.2M | -- | -- |
| Shareholders' Equity | $133.9M↑10% | $133.9M↑10% | $131.1M↑10% | $129.6M↑11% | $128.3M↑10% | $117.0M↓8% | $126.6M | $126.1M↓4% | $131.4M |
| Current Ratio | 5.06↑66% | 5.06↑66% | 5.58↑117% | 5.37↑91% | 3.04↑5% | 2.89↓5% | 3.04↓74% | 11.74↓4% | 12.29 |
| Debt / Equity | 0.10↓59% | 0.10↓59% | 0.15↓39% | 0.18↓36% | 0.20↓29% | 0.28↓2% | 0.29 | — | — |
| Operating Cash Flow | $20.0M↑69% | $4.7M↑48% | $8.6M↑89% | -$467.0K↓112% | $18.7M↑283% | $4.9M↑168% | -$7.2M↓168% | $10.7M↑1367% | $726.0K |
| Free Cash Flow | $19.9M↑69% | $4.7M↑48% | $8.6M↑88% | -$488.0K↓113% | $18.7M↑291% | $4.8M↑165% | -$7.3M↓169% | $10.6M↑1590% | $625.7K |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Business Services
OPRX vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUTOMATIC DATA PROCESSING INCADP | $122.3B | $309.93 | $21.9B | $4.4B | 73.2% | 0.82 | 24.2% | 1.05 | 4/9 | 5/9 | 3/7 | 0/3 | F-Score 6 | 5/11 |
| ELECTRONIC ARTS INC.EA | $52.9B | $209.70 | $7.5B | $887.0M | 13.1% | 0.22 | 15.4% | 1.05 | 1/9 | 4/9 | 4/7 | 0/3 | F-Score 6 | 6/11 |
| Rubrik, Inc.RBRK | $22.6B | $109.88 | $1.3B | $348.8M | 67.1% | — | -26.2% | 1.69 | 1/9 | 0/9 | 2/7 | 0/3 | F-Score 6 | 2/11 |
| AECOMACM | $9.1B | $70.50 | $16.1B | $561.8M | 22.5% | 1.09 | 6.4% | 1.14 | 1/9 | 3/9 | 3/7 | 1/3 | F-Score 8 | 2/11 |
| COMMVAULT SYSTEMS INCCVLT | $6.2B | $152.07 | $1.2B | $70.7M | 942.8% | — | 6.3% | 1.95 | 1/9 | 2/9 | 4/7 | 0/3 | F-Score 6 | 6/11 |
| WPP plcWPP | $6.0B | $27.79 | $18.2B | $289.5M | -8.5% | 1.94 | 2.8% | 0.89 | 1/9 | 2/9 | 1/7 | 0/3 | F-Score 3 | 2/11 |
| VARONIS SYSTEMS INCVRNS | $5.6B | $48.94 | $623.5M | $129.3M | -21.6% | 0.76 | -23.5% | 1.97 | 1/9 | 0/9 | 1/7 | 0/3 | F-Score 5 | 1/11 |
| ROBERT HALF INC.RHI | $4.3B | $42.00 | $5.4B | $133.0M | 10.4% | — | 1.4% | 1.53 | 2/9 | 5/9 | 1/7 | 0/3 | F-Score 5 | 2/11 |